Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Family Larsson-Rosenquist Foundation (FLRF) has awarded £2.9 million to the Nuffield Department of Women’s & Reproductive Health at the University of Oxford to establish a research centre focused on studying the endocrinology of human lactation.

Image credit: FatCamera

Breast milk is known to provide the best source of nutrition for newborns and children; it also has a positive impact on their long-term health and development. Although valuable research has already been conducted in the field of human lactation, many questions remain unanswered – such as how hormones control milk production and weaning, and influence the mother’s long-term health. FLRF aims to support mothers and children worldwide by funding long-term research on the endocrinology of human lactation at the University of Oxford so as to fill these knowledge gaps.

Find out more (Department of Women's and Reproductive Health website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.